Summit Therapeutics (SMMT) EGM 2026 summary

Opening remarks and agenda

• Special meeting convened with management, board members, and outside counsel present; proxy materials and meeting rules were available online.

• Notice and proxy statement mailed on or about October 19, 2026, to holders of record as of October 1, 2026; proxies representing a majority of eligible votes established a quorum.

• The meeting agenda contained one voting item, followed by a report of preliminary results and shareholder questions.

Specific resolutions to be voted on

• Proposal to amend the restated certificate of incorporation to increase authorized common shares by 1 billion, from 1 billion to 2 billion.

Overview of voting outcomes

• The preliminary inspector’s report determined the amendment was approved; final results were to be disclosed on Form 8-K within four business days of the meeting.